Antidepressants May Improve Outcomes in People with Diabetes and Depression

People with diabetes and depression who take antidepressants may have a lower risk of death and of serious diabetes complications, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.

People with diabetes face a higher risk of depression, which makes them more likely to die or develop diabetes complications including heart and kidney disease, stroke, eye, and foot problems. Depression makes diabetes complications worse due to stress, body weight changes, and lack of exercise.

“People with depression and diabetes have poorer health outcomes than those with diabetes alone, and regular antidepressant treatment could lower their risk of complications,” said study author Shi-Heng Wang, PhD, of the China Medical University in Taichung, Taiwan.

“People who adhere to their antidepressants have better diabetes outcomes and quality of life than those with poor adherence,” said study author Chi-Shin Wu, MD, PhD, of the National Taiwan University Hospital in Taipei, Taiwan.

The researchers conducted a nationwide retrospective cohort study of 36,276 patients with depression and diabetes to determine if antidepressants could improve diabetes outcomes. They found regular antidepressant treatment was associated with a lower risk of death and heart disease.

Other authors of the study include: Le-Yin Hsu of the National Taiwan University in Taipei, Taiwan; and Yi-Jiun Pan of the China Medical University in Taichung, Taiwan.

The manuscript received funding from the Ministry of Science and Technology, the China Medical University, and the Ministry of Health and Welfare.

The manuscript, “Associations Between Antidepressant Use and Advanced Diabetes Outcomes in Patients with Depression and Diabetes Mellitus,” was published online, ahead of print.

You may also like

  • Liraglutide Increases Insulin Sensitivity Independent of Weight Loss, Study Shows

    Liraglutide, the glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat type 2 diabetes and obesity, can lead to rapid improvement in insulin sensitivity, according to a study recently published in Diabetes. “We know that GLP-1R agonists promote weight loss, but we were surprised to find that the GLP-1R agonist liraglutide also has rapid effects on…

  • COVID-19 Vaccines and Hyperglycemia in Patients with Type 1 Diabetes

    While proven to be safe, the COVID-19 vaccines could cause some people with type 1 diabetes to see their blood sugar to temporarily spike. The key for both patient and provider is to remain vigilant with glucose testing and insulin dosing post-jab to maintain glycemic control.  In the summer of 2021, a 24-year-old woman presented…